Comparing the Effects of Tamoxifen and Avenanthramide B on Liver Enzymes
Author Information
Author(s): Lim Hakseong, Hwang Sungbo, Cho Seung-Hak, Bak Young-Seok, Yang Woong-Suk, Park Daeui, Kim Cheorl-Ho
Primary Institution: Sungkyunkwan University
Hypothesis
How do tamoxifen and avenanthramide B affect porcine liver esterase activity?
Conclusion
Both tamoxifen and avenanthramide B inhibit porcine liver esterase activity, with avenanthramide B showing similar effects to tamoxifen.
Supporting Evidence
- Tamoxifen and avenanthramide B both inhibit porcine liver esterase activity.
- Avenanthramide B interacts with specific residues in the enzyme, enhancing its inhibitory effect.
- Tamoxifen has been shown to induce hepatotoxicity, which is relevant for its use in humans.
- Understanding the interaction between these compounds and liver enzymes can inform drug development.
Takeaway
This study found that a substance in oats, avenanthramide B, can block a liver enzyme just like a cancer drug called tamoxifen.
Methodology
The study used molecular simulations and physiological assays to assess the inhibitory effects of tamoxifen and avenanthramide B on porcine liver esterase.
Limitations
The specific molecular mechanism of inhibition remains unclear and requires further structural studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website